Feb 21, 2023 / 03:00PM GMT
Yigal Dov Nochomovitz - Citigroup Inc., Research Division - Director
Okay, great. Welcome back everyone. It is Yigal Nochomovitz one of the biotech analysts at Citi. This is the first of 3 days of our 1Q 2023 Oncology Summit the third session of the morning. My great pleasure to have with me from Gracell Biotechnologies, the CFO, Kevin Xie. Kevin welcome thank you so much for taking some time. I think a lot of people know the company, but there may be some that need a little bit of a background. If you could spend a few minutes just giving a quick overview of Gracell and the pipeline and what should investors be looking forward to in terms of updates for this year. Thanks.
Yili Xie - Gracell Biotechnologies Inc. - CFO
Thank you, Yigal. Thanks Citi who invite us through this Oncology Leadership Summit. Good morning, everybody. Gracell is a global clinical stage biopharma company focused on next-generation cell therapy. We now have 2 platform technologies in the CAR-T space. One is FasTCAR which is the next-day manufacture autologous CAR T and the second is the
Gracell Biotechnologies Inc at Citi Virtual Oncology Leadership Summit Transcript
Feb 21, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers